- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06024928
Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes (AID-BIT)
November 29, 2023 updated by: Anas El Fathi, University of Virginia
Short Use of Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes: A Pilot Study
The purpose of this clinical trial is to test the safety and feasibility of using an Automated Insulin Device (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
Participants will be randomized to either the control group or the experimental group.
If in the experimental group, the participant will use an insulin pump with Control-IQ Technology (Tandem Diabetes Care) for ten days.
Researchers will compare the glycemic control of the experimental group to the control group.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will involve 20 people with Type 2 Diabetes who are 18 years or older.
The study will be performed at the University of Virginia (UVA), with screening procedures taking place either virtually or at the Clinical Research Unit (CRU) at UVA.
All participants will undergo a 10-day run-in phase with a blinded Dexcom Generation 6 Continuous Glucose Monitor (CGM).
Participants will be randomized (1:1) to either the Control (CTR) Group or the Experimental (EXP) Group.
In the EXP Group, participants will use an Automated Insulin Device (AID) for 10 days in the Basal Insulin Titration (BIT) Phase then return to their original therapy (basal insulin using pen) using the new setting in the Maintenance Phase (MP).
The total daily insulin (TDI) requirement during the BIT Phase will be translated to a basal insulin dose.
During the same 10 days, in the CTR group, participants will use an unblinded CGM and will be contacted by a study physician as per standard care to adjust their insulin doses if needed.
Both groups will then go into a 10-days maintenance period using a blinded CGM.
Outcomes will be measured in the last 7 days of the BIT and Maintenance Phases.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ralf M Nass, MD
- Phone Number: 434-982-0868
- Email: rmn9a@uvahealth.org
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia Center for Diabetes Technology
-
Contact:
- Ralf M Nass, MD
- Phone Number: 434-982-0868
- Email: rmn9a@uvahealth.org
-
Contact:
- Lianna H Smith
- Phone Number: 434-466-4856
- Email: lhs7px@uvahealth.org
-
Sub-Investigator:
- Ralf M Nass, MD
-
Sub-Investigator:
- Boris Kovatchev, PhD
-
Principal Investigator:
- Anas El Fathi, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18.0 years old at time of consent.
- Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least one year.
- HbA1c ≥ 7.5%.
- Currently using an approved long-acting insulin for at least six months (e.g., insulin glargine, insulin degludec)
- Willingness to discontinue a personal CGM during the duration of the study.
- Access to the internet and willingness to upload data during the study as needed.
- If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
- Willingness not to start any new non-insulin glucose-lowering agent during the trial (including metformin/biguanides, Glucagon-like peptide (GLP)-1 receptor agonists, pramlintide, Dipeptidyl peptidase (DPP)-4 inhibitors, sulfonylureas and nutraceuticals).
Exclusion Criteria:
- Treatment with meglitinides/sulfonylureas.
- Currently using an approved intermediate (e.g., insulin Neutral Protamine Hagedorn (NPH)) or rapid insulin for at least six months (e.g., insulin aspart, insulin lispro, insulin regular).
- Currently being treated for a seizure disorder.
- A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol, such as but not limited to, the following examples: a) Inpatient psychiatric treatment in the past 6 months, b) Presence of a known adrenal disorder, c) Uncontrolled thyroid disease.
- Currently pregnant or intent to become pregnant during the trial.
- Currently breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Automated Insulin Delivery in the Basal Insulin Titration Phase
Participants will use Automated Insulin Delivery (AID) for 10 days in the Basal Insulin Titration (BIT) Phase.
This group will then return to their original home therapy (basal insulin using pen) using the new setting in the Maintenance Phase (MP) with a blinded CGM.
The total daily insulin (TDI) requirement during the BIT Phase will be translated to a basal insulin dose.
|
Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
Other Names:
|
No Intervention: Standard Care with Study Continuous Glucose Monitor
Participants will use a study Continuous Glucose Monitor (CGM) along with their original home therapy and will be contacted by a study physician as per standard care to adjust their insulin doses if needed.
This group will then transition into a 10-day Maintenance Phase (MP) using a blinded CGM, where the basal dose will be maintained.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
System Testing survey
Time Frame: 14 days
|
Receiving feedback from the participants regarding system functionality.
|
14 days
|
Percent Time in Range
Time Frame: 14 days
|
The percent of time spent within glycemic range of 70 to 180 mg/mL.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Time Below Range
Time Frame: 14 days
|
The percent of time spent below 70 mg/mL.
|
14 days
|
Percent Time Above Range
Time Frame: 14 days
|
The percent of time spent above 180 mg/mL.
|
14 days
|
Percent Time in Tighter Range
Time Frame: 14 days
|
The percent of time spent within glycemic range of 70 to 140 mg/mL.
|
14 days
|
Percent Time Below Range (Hypoglycemia)
Time Frame: 14 days
|
The percent of time spent below 54 mg/mL.
|
14 days
|
Percent Time Above Range (Hyperglycemia)
Time Frame: 14 days
|
The percent of time spent above 250 mg/mL.
|
14 days
|
Mean glucose reading measured by Continuous Glucose Monitor (CGM)
Time Frame: 14 days
|
Glucose variability measured by coefficient of variation.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anas El Fathi, PhD, University of Virginia Center for Diabetes Technology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 14, 2025
Study Registration Dates
First Submitted
August 29, 2023
First Submitted That Met QC Criteria
September 5, 2023
First Posted (Actual)
September 6, 2023
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 230316
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Will follow the NIH Data Sharing Policy and Implementation Guidance on sharing research resources for research purposes to qualified individuals in the scientific community.
IPD Sharing Time Frame
Data will be made available after the primary publications of the study.
IPD Sharing Access Criteria
The Data Sharing Agreements will be formulated by the study team.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... and other collaboratorsCompletedType 2 Diabetes Mellitus
Clinical Trials on Control-IQ use in Type 2 Diabetes under basal insulin injections
-
Glostrup University Hospital, CopenhagenUnknownDiabetes Mellitus | Diabetic RetinopathyDenmark
-
Universiti Sains MalaysiaCompleted
-
Cairo UniversityUnknownPremenstrual SyndromeEgypt
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands